Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Prostate Cancer

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 136 articles: HTML format

Single Articles

May 2021
1. MARTINEZ RS, Salji MJ, Rushworth L, Ntala C, et al
   SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer.
   Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-3694.
   PubMed     Abstract available
   
   
   March 2021
2. CARRENO DV, Corro NB, Cerda-Infante JF, Echeverria CE, et al
   Dietary Fructose Promotes Prostate Cancer Growth.
   Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-19-0456.
   PubMed     Abstract available
   
   
   
3. SHI L, Yan Y, He Y, Yan B, et al
   Mutated SPOP E3 ligase promotes 17betaHSD4 protein degradation to drive androgenesis and prostate cancer progression.
   Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-3258.
   PubMed     Abstract available
   
   
   
4. WANG J, Wang J, Dai J, Jung Y, et al
   Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer.
   Cancer Res. 2021;81:1623.
   PubMed    
   
   
   February 2021
5. UNNO K, Chalmers ZR, Pamarthy S, Vatapalli R, et al
   Activated ALK Cooperates with N-Myc via Wnt/beta-catenin Signaling to Induce Neuroendocrine Prostate Cancer.
   Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-3351.
   PubMed     Abstract available
   
   
   
6. XIE J, Rice MA, Chen Z, Cheng Y, et al
   In vivo imaging of methionine aminopeptidase II for prostate cancer risk stratification.
   Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-2969.
   PubMed     Abstract available
   
   
   
7. HAN D, Owiredu JN, Healy BM, Li M, et al
   Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression.
   Cancer Res. 2021 Feb 25. pii: 0008-5472.CAN-20-3042.
   PubMed     Abstract available
   
   
   
8. PASCHALIS A, Welti J, Neeb AJ, Yuan W, et al
   JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
   Cancer Res. 2021;81:1087-1100.
   PubMed     Abstract available
   
   
   
9. STROBL MAR, West J, Viossat Y, Damaghi M, et al
   Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
   Cancer Res. 2021;81:1135-1147.
   PubMed     Abstract available
   
   
   
10. CENTENERA MM, Scott JS, Machiels J, Nassar ZD, et al
    ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer.
    Cancer Res. 2021 Feb 5. pii: 0008-5472.CAN-20-2511.
    PubMed     Abstract available
    
    
    January 2021
11. GHOOCHANI A, Hsu EC, Aslan M, Rice MA, et al
    Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-3477.
    PubMed     Abstract available
    
    
    
12. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available
    
    
    
13. SOLEIMANY AP, Kirkpatrick JD, Su S, Dudani JS, et al
    Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer.
    Cancer Res. 2021;81:213-224.
    PubMed     Abstract available
    
    
    December 2020
14. ALPSOY A, Utturkar SM, Carter BC, Dhiman A, et al
    BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression.
    Cancer Res. 2020 Dec 21. pii: 0008-5472.CAN-20-1417.
    PubMed     Abstract available
    
    
    
15. HAGIWARA M, Yasumizu Y, Yamashita N, Rajabi H, et al
    MUC1-C ACTIVATES THE BAF (mSWI/SNF) COMPLEX IN PROSTATE CANCER STEM CELLS.
    Cancer Res. 2020 Dec 15. pii: 0008-5472.CAN-20-2588.
    PubMed     Abstract available
    
    
    
16. EMAMI NC, Cavazos TB, Rashkin SR, Graff RE, et al
    A large-scale association study detects novel rare variants, risk genes, functional elements, and polygenic architecture of prostate cancer susceptibility.
    Cancer Res. 2020 Dec 8. pii: 0008-5472.CAN-20-2635.
    PubMed     Abstract available
    
    
    
17. GAO L, Zhang W, Zhang J, Liu J, et al
    KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer.
    Cancer Res. 2020 Dec 4. pii: 0008-5472.CAN-20-1965.
    PubMed     Abstract available
    
    
    November 2020
18. BOWEN C, Shibata M, Zhang H, Bergren SK, et al
    CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.
    Cancer Res. 2020;80:4805-4814.
    PubMed     Abstract available
    
    
    
19. LI G, Kanagasabai T, Lu W, Zou MR, et al
    KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Cancer Res. 2020;80:4633-4643.
    PubMed     Abstract available
    
    
    October 2020
20. SAWANT DESSAI A, Palestino Dominguez M, Chen UI, Hasper J, et al
    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1708.
    PubMed     Abstract available
    
    
    September 2020
21. BEKETOVA E, Fang S, Owens JL, Liu S, et al
    Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1228.
    PubMed     Abstract available
    
    
    
22. SHAH N, Kesten N, Font-Tello A, Chang MEK, et al
    ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-2044.
    PubMed     Abstract available
    
    
    
23. WANG C, Li J
    A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes.
    Cancer Res. 2020 Sep 9. pii: 0008-5472.CAN-20-1791.
    PubMed     Abstract available
    
    
    August 2020
24. SCHONHOFT JD, Zhao JL, Jendrisak A, Carbone EA, et al
    Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1216.
    PubMed     Abstract available
    
    
    June 2020
25. XU S, Fan L, Jeon HY, Zhang F, et al
    p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer.
    Cancer Res. 2020 Jun 10. pii: 0008-5472.CAN-20-0233.
    PubMed     Abstract available
    
    
    
26. SETTON JS, Powell SN
    Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
    Cancer Res. 2020;80:2085-2086.
    PubMed     Abstract available
    
    
    May 2020
27. LI S, Fong KW, Gritsina G, Zhang A, et al
    Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
    Cancer Res. 2020;80:2072.
    PubMed    
    
    
    
28. HARLEMON M, Ajayi O, Kachambwa P, Kim MS, et al
    A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa.
    Cancer Res. 2020 May 11. pii: 0008-5472.CAN-19-2165.
    PubMed     Abstract available
    
    
    
29. WAHDAN-ALASWAD RS, Song K, Krebs TL, Shola DTN, et al
    Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling.
    Cancer Res. 2020;80:1902.
    PubMed    
    
    
    April 2020
30. WU H, You L, Li Y, Zhao Z, et al
    Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance.
    Cancer Res. 2020 Apr 27. pii: 0008-5472.CAN-19-2549.
    PubMed     Abstract available
    
    
    
31. MAO N, Gao D, Hu W, Gadal S, et al
    Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Cancer Res. 2020;80:1428-1437.
    PubMed     Abstract available
    
    
    March 2020
32. RAFIEI S, Fitzpatrick K, Liu D, Cai MY, et al
    ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer.
    Cancer Res. 2020 Mar 3. pii: 0008-5472.CAN-19-3126.
    PubMed     Abstract available
    
    
    February 2020
33. HANKEY W, Chen Z, Wang Q
    Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors.
    Cancer Res. 2020 Feb 24. pii: 0008-5472.CAN-19-3447.
    PubMed     Abstract available
    
    
    
34. CHA HR, Lee JH, Ponnazhagan S
    Revisiting Immunotherapy: A Focus on Prostate Cancer.
    Cancer Res. 2020 Feb 17. pii: 0008-5472.CAN-19-2948.
    PubMed     Abstract available
    
    
    
35. CERASUOLO M, Maccarinelli F, Coltrini D, Mahmoud AM, et al
    Modeling acquired resistance to the second-generation androgen receptor antagonist enzalutamide in the TRAMP model of prostate cancer.
    Cancer Res. 2020 Feb 6. pii: 0008-5472.CAN-18-3637.
    PubMed     Abstract available
    
    
    January 2020
36. NESSLER I, Khera E, Vance S, Kopp A, et al
    Increased Tumor Penetration of Single-Domain Antibody Drug Conjugates Improves In Vivo Efficacy in Prostate Cancer Models.
    Cancer Res. 2020 Jan 15. pii: 0008-5472.CAN-19-2295.
    PubMed     Abstract available
    
    
    
37. SAHA S, Kiran M, Kuscu C, Chatrath A, et al
    Long noncoding RNA DRAIC inhibits prostate cancer progression by interacting with IKK to inhibit NF-kappaB activation.
    Cancer Res. 2020 Jan 3. pii: 0008-5472.CAN-19-3460.
    PubMed     Abstract available
    
    
    December 2019
38. ZHANG D, He D, Xue Y, Wang R, et al
    Editor's Note: PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 Pathway.
    Cancer Res. 2019;79:6054.
    PubMed    
    
    
    November 2019
39. MCCANN JJ, Vasilevskaya IA, Poudel Neupane N, Shafi AA, et al
    USP22 functions as an oncogenic driver in prostate cancer by regulating cell proliferation and DNA repair.
    Cancer Res. 2019 Nov 18. pii: 0008-5472.CAN-19-1033.
    PubMed     Abstract available
    
    
    
40. PATEL VL, Busch EL, Friebel TM, Cronin A, et al
    Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.
    Cancer Res. 2019 Nov 13. pii: 0008-5472.CAN-19-1840.
    PubMed     Abstract available
    
    
    
41. WANG X, Ramamurthy G, Shirke AA, Walker E, et al
    Photodynamic Therapy is an Effective Adjuvant Therapy for Image-Guided Surgery in Prostate Cancer.
    Cancer Res. 2019 Nov 12. pii: 0008-5472.CAN-19-0201.
    PubMed     Abstract available
    
    
    
42. PATEL R, Brzezinska EA, Repiscak P, Ahmad I, et al
    Activation of beta-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer.
    Cancer Res. 2019 Nov 12. pii: 0008-5472.CAN-19-1684.
    PubMed     Abstract available
    
    
    October 2019
43. VALCARCEL-JIMENEZ L, Macchia A, Crosas-Molist E, Schaub-Clerigue A, et al
    PGC1alpha suppresses prostate cancer cell invasion through ERRalpha transcriptional control.
    Cancer Res. 2019 Oct 8. pii: 0008-5472.CAN-19-1231.
    PubMed     Abstract available
    
    
    September 2019
44. SHAPOVALOVA M, Lee JK, Li Y, Vander Griend DJ, et al
    PEG10 promoter-driven expression of reporter genes enables molecular imaging of lethal prostate cancer.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-19-2181.
    PubMed     Abstract available
    
    
    
45. TAYLOR RA, Watt MJ
    Unsuspected Protumorigenic Signaling Role for the Oncometabolite GABA in Advanced Prostate Cancer.
    Cancer Res. 2019;79:4580-4581.
    PubMed     Abstract available
    
    
    
46. GENG C, Rajapakshe K, Shah SS, Shou J, et al
    Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.
    Cancer Res. 2019;79:4552.
    PubMed    
    
    
    August 2019
47. CAI C, Han D, Chen S, Han W, et al
    ZBTB7A mediates the transcriptional repression activity of the androgen receptor in prostate cancer.
    Cancer Res. 2019 Aug 23. pii: 0008-5472.CAN-19-0815.
    PubMed     Abstract available
    
    
    
48. KAWAMURA N, Nimura K, Saga K, Ishibashi A, et al
    SF3B2-mediated RNA splicing drives human prostate cancer progression.
    Cancer Res. 2019 Aug 20. pii: 0008-5472.CAN-18-3965.
    PubMed     Abstract available
    
    
    July 2019
49. RUBENSTEIN CS, Gard JMC, Wang M, McGrath JE, et al
    Gene editing of alpha6 integrin inhibits muscle invasive networks and increases cell-cell biophysical properties in prostate cancer.
    Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-19-0868.
    PubMed     Abstract available
    
    
    
50. WU L, Shu X, Bao J, Guo X, et al
    Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk.
    Cancer Res. 2019 Jul 23. pii: 0008-5472.CAN-18-3997.
    PubMed     Abstract available
    
    
    June 2019
51. BOWEN C, Ostrowski MC, Leone G, Gelmann EP, et al
    Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.
    Cancer Res. 2019 Jun 18. pii: 0008-5472.CAN-18-4110.
    PubMed     Abstract available
    
    
    
52. GAO Y, Chen L, Du Z, Gao W, et al
    Glutamate decarboxylase 65 signals through the androgen receptor to promote castration resistance in prostate cancer.
    Cancer Res. 2019 Jun 10. pii: 0008-5472.CAN-19-0700.
    PubMed     Abstract available
    
    
    May 2019
53. WU L, Wang J, Cai Q, Cavazos TB, et al
    Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-18-3536.
    PubMed     Abstract available
    
    
    
54. GORDON JA, Noble JW, Midha A, Derakhshan F, et al
    Upregulation of Scavenger receptor B1 is required for steroidogenic and non-steroidogenic cholesterol metabolism in prostate cancer.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2529.
    PubMed     Abstract available
    
    
    
55. KAMINSKI L, Torrino S, Dufies M, Djabari Z, et al
    PGC-1alpha inhibits polyamine synthesis to suppress prostate cancer aggressiveness.
    Cancer Res. 2019 May 7. pii: 0008-5472.CAN-18-2043.
    PubMed     Abstract available
    
    
    April 2019
56. JIANG S, Wang X, Song D, Liu X, et al
    Cholesterol induces epithelial-to-mesenchymal transition of prostate cancer cells by suppressing degradation of EGFR through APMAP.
    Cancer Res. 2019 Apr 15. pii: 0008-5472.CAN-18-3295.
    PubMed     Abstract available
    
    
    
57. LI S, Fong KW, Gritsina G, Zhang A, et al
    Activation of MAPK signaling by CXCR7 leads to enzalutamide resistance in prostate cancer.
    Cancer Res. 2019 Apr 5. pii: 0008-5472.CAN-18-2812.
    PubMed     Abstract available
    
    
    March 2019
58. LIU C, Gao AC
    IFNgamma, a Double-Edged Sword in Cancer Immunity and Metastasis.
    Cancer Res. 2019;79:1032-1033.
    PubMed     Abstract available
    
    
    February 2019
59. KUMAR R, Bhat TA, Walsh EM, Chaudhary AK, et al
    Cytochrome c-deficiency Confers Apoptosome and Mitochondrial Dysfunction in African-American Men with Prostate Cancer.
    Cancer Res. 2019 Feb 14. pii: 0008-5472.CAN-18-2383.
    PubMed     Abstract available
    
    
    
60. WU L, Yi B, Wei S, Yao D, et al
    Loss of Foxp3 and Tsc1 Accelerate Prostate Cancer Progression through a Synergistic Transcriptional and Post-translational Regulation of c-MYC.
    Cancer Res. 2019 Feb 7. pii: 0008-5472.CAN-18-2049.
    PubMed     Abstract available
    
    
    January 2019
61. VUMMIDI GIRIDHAR P, Williams K, VonHandorf AP, Deford PL, et al
    Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Cancer Res. 2019 Jan 9. pii: 0008-5472.CAN-18-1753.
    PubMed     Abstract available
    
    
    November 2018
62. LO UG, Pong RC, Yang D, Gandee L, et al
    IFN-r-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via microRNA processing.
    Cancer Res. 2018 Nov 30. pii: 0008-5472.CAN-18-2207.
    PubMed     Abstract available
    
    
    
63. TRAVIS RC, Perez-Cornago A, Appleby PN, Albanes D, et al
    A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk.
    Cancer Res. 2018 Nov 13. pii: 0008-5472.CAN-18-2318.
    PubMed     Abstract available
    
    
    October 2018
64. 
    Retraction: Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo.
    Cancer Res. 2018;78:6028.
    PubMed    
    
    
    September 2018
65. PENFOLD L, Woods A, Muckett P, Nikitin AY, et al
    CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0585.
    PubMed     Abstract available
    
    
    
66. RUSSO JW, Gao C, Bhasin SS, Voznesensky OS, et al
    Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0687.
    PubMed     Abstract available
    
    
    
67. 
    Retraction: Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer.
    Cancer Res. 2018;78:5475.
    PubMed    
    
    
    
68. 
    Retraction: Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells.
    Cancer Res. 2018;78:5473.
    PubMed    
    
    
    
69. 
    Retraction: Inhibition of Angiogenesis and Invasion by 3,3'-Diindolylmethane Is Mediated by the Nuclear Factor-kappaB Downstream Target Genes MMP-9 and uPA that Regulated Bioavailability of Vascular Endothelial Growth Factor in Prostate Cancer.
    Cancer Res. 2018;78:5471.
    PubMed    
    
    
    
70. 
    Editor's Note: In vitro and In vivo Molecular Evidence for Better Therapeutic Efficacy of ABT-627 and Taxotere Combination in Prostate Cancer.
    Cancer Res. 2018;78:5465.
    PubMed    
    
    
    
71. JARATLERDSIRI W, Chan EKF, Gong T, Petersen DC, et al
    Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive, High-Risk Prostate Cancer.
    Cancer Res. 2018 Sep 14. pii: 0008-5472.CAN-18-0254.
    PubMed     Abstract available
    
    
    
72. GILLARD M, Javier R, Ji Y, Zheng SL, et al
    Elevated Stromal Inflammatory Mediators Promote Prostate Cancer Progression in African American Men.
    Cancer Res. 2018 Sep 4. pii: 0008-5472.CAN-17-3810.
    PubMed     Abstract available
    
    
    
73. 
    Correction: Cofilin Drives Cell-Invasive and Metastatic Responses to TGF-beta in Prostate Cancer.
    Cancer Res. 2018;78:5180.
    PubMed    
    
    
    August 2018
74. XIAO L, Tien JC, Vo J, Tan M, et al
    Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer.
    Cancer Res. 2018 Aug 22. pii: 0008-5472.CAN-18-0941.
    PubMed     Abstract available
    
    
    July 2018
75. CHEN S, Cai C, Sowalsky AG, Ye H, et al
    BMX-mediated regulation of multiple tyrosine kinases contributes to castration resistance in prostate cancer.
    Cancer Res. 2018 Jul 16. pii: 0008-5472.CAN-17-3615.
    PubMed     Abstract available
    
    
    
76. 
    Retraction: Histone Deacetylase Inhibitors Sensitize Prostate Cancer Cells to Agents that Produce DNA Double-Strand Breaks by Targeting Ku70 Acetylation.
    Cancer Res. 2018;78:4097.
    PubMed    
    
    
    
77. 
    Correction: Regulation of Minichromosome Maintenance Gene Family by MicroRNA-1296 and Genistein in Prostate Cancer.
    Cancer Res. 2018;78:3740.
    PubMed    
    
    
    June 2018
78. HOMPLAND T, Hole KH, Ragnum HB, Aarnes EK, et al
    Combined MR imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness in prostate cancer patients.
    Cancer Res. 2018 Jun 26. pii: 0008-5472.CAN-17-3806.
    PubMed     Abstract available
    
    
    
79. KOLIJN K, Verhoef EI, Smid M, Bottcher R, et al
    Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression.
    Cancer Res. 2018 Jun 19. pii: 0008-5472.CAN-17-3752.
    PubMed     Abstract available
    
    
    
80. 
    Correction: miRNA-708 Control of CD44(+) Prostate Cancer-Initiating Cells.
    Cancer Res. 2018;78:3404.
    PubMed    
    
    
    
81. 
    Retraction: Demethylation-Linked Activation of Urokinase Plasminogen Activator Is Involved in Progression of Prostate Cancer.
    Cancer Res. 2018;78:3397.
    PubMed    
    
    
    
82. LIU J, Chen G, Liu Z, Liu S, et al
    Aberrant FGFR tyrosine kinase signaling enhances the Warburg effect by reprogramming LDH isoform expression and activity in prostate cancer.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3226.
    PubMed     Abstract available
    
    
    
83. LI X, Wang X, Song W, Xu H, et al
    Oncogenic properties of NEAT1 in prostate cancer cells depend on the CDC5L-AGRN transcriptional regulation circuit.
    Cancer Res. 2018 Jun 5. pii: 0008-5472.CAN-18-0688.
    PubMed     Abstract available
    
    
    May 2018
84. LU X, Pan X, Wu CJ, Zhao D, et al
    An in vivo screen identifies PYGO2 as a driver for metastatic prostate cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3564.
    PubMed     Abstract available
    
    
    
85. MOSES MA, Kim YS, Rivera-Marquez GM, Oshima N, et al
    Targeting the Hsp40/Hsp70 chaperone axis as a novel strategy to treat castration-resistant prostate cancer.
    Cancer Res. 2018 May 15. pii: 0008-5472.CAN-17-3728.
    PubMed     Abstract available
    
    
    April 2018
86. ZHANG Z, Cheng L, Li J, Farah E, et al
    Inhibition of the Wnt/beta-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.
    Cancer Res. 2018 Apr 26. pii: 0008-5472.CAN-17-3006.
    PubMed     Abstract available
    
    
    March 2018
87. DAS SK, Pradhan AK, Bhoopathi P, Talukdar S, et al
    The MDA-9/Syntenin/IGF-1R/STAT3 axis directs prostate cancer invasion.
    Cancer Res. 2018 Mar 23. pii: 0008-5472.CAN-17-2992.
    PubMed     Abstract available
    
    
    
88. YU G, Cheng CJ, Lin SC, Lee YC, et al
    Organelle-derived acetyl-CoA promotes prostate cancer cell survival, migration, and metastasis via activation of calmodulin kinase II.
    Cancer Res. 2018 Mar 13. pii: 0008-5472.CAN-17-2392.
    PubMed     Abstract available
    
    
    
89. YU-LEE LY, Yu G, Lee YC, Lin SC, et al
    Osteoblast-secreted factors mediate dormancy of metastatic prostate cancer in the bone via activation of the TGFbetaRIII-p38MAPK-pS249/T252RB pathway.
    Cancer Res. 2018 Mar 7. pii: 0008-5472.CAN-17-1051.
    PubMed     Abstract available
    
    
    February 2018
90. CI X, Hao J, Dong X, Choi SYC, et al
    Heterochromatin protein 1alpha mediates development and aggressiveness of neuroendocrine prostate cancer.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3677.
    PubMed     Abstract available
    
    
    
91. SORRENTINO C, Ciummo SL, Cipollone G, Caputo S, et al
    Interleukin-30/IL-27p28 shapes prostate cancer stem-like cell behavior and is critical for tumor onset and metastasization.
    Cancer Res. 2018 Feb 27. pii: 0008-5472.CAN-17-3117.
    PubMed     Abstract available
    
    
    
92. LACHANCE J, Berens AJ, Hansen MEB, Teng AK, et al
    Genetic hitchhiking and population bottlenecks contribute to prostate cancer disparities in men of African descent.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-1550.
    PubMed     Abstract available
    
    
    
93. XIAO L, Wang Y, Xu K, Hu H, et al
    Nuclear receptor LRH-1 functions to promote castration-resistant growth of prostate cancer via its promotion of intratumoral androgen biosynthesis.
    Cancer Res. 2018 Feb 8. pii: 0008-5472.CAN-17-2341.
    PubMed     Abstract available
    
    
    
94. JUNG Y, Cackowski FC, Yumoto K, Decker A, et al
    CXCL12gamma Promotes Development of Metastatic Castration Resistant Prostate Cancer by Induction of Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2018 Feb 5. pii: 0008-5472.CAN-17-2332.
    PubMed     Abstract available
    
    
    
95. BHAGIRATH D, Yang TL, Bucay N, Sekhon K, et al
    MicroRNA-1246 is an exosomal biomarker for aggressive prostate cancer.
    Cancer Res. 2018 Feb 1. pii: 0008-5472.CAN-17-2069.
    PubMed     Abstract available
    
    
    January 2018
96. MCCLINCH K, A Avelar R, Callejas D, Izadmehr S, et al
    Small molecule activators of protein phosphatase 2A for the treatment of castration-resistant prostate cancer.
    Cancer Res. 2018 Jan 22. pii: 0008-5472.CAN-17-0123.
    PubMed     Abstract available
    
    
    
97. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Abstract available
    
    
    
98. ROSSNAGL S, Ghura H, Groth C, Altrock E, et al
    A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow.
    Cancer Res. 2018;78:129-142.
    PubMed     Abstract available
    
    
    December 2017
99. COUTURE F, Sabbagh R, Kwiatkowska A, Desjardins R, et al
    PACE4 Undergoes an Oncogenic Alternative Splicing Switch in Cancer.
    Cancer Res. 2017;77:6863-6879.
    PubMed     Abstract available
    
    
    
100. HORNING AM, Wang Y, Lin CK, Louie AD, et al
     Single-cell RNA-seq reveals a subpopulation of prostate cancer cells with enhanced cell cycle-related transcription and attenuated androgen response.
     Cancer Res. 2017 Dec 12. pii: 0008-5472.CAN-17-1924.
     PubMed     Abstract available
     
     
     
101. YOU S, Freeman MR
     A Systems Approach to Prostate Cancer Classification-Response.
     Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-17-0239.
     PubMed    
     
     
     
102. THYSELL E, Ylitalo EB, Jernberg E, Bergh A, et al
     A Systems Approach to Prostate Cancer Classification-Letter.
     Cancer Res. 2017 Dec 6. pii: 0008-5472.CAN-16-3231.
     PubMed    
     
     
     
103. YANG Y, Blee AM, Wang D, An J, et al
     Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
     Cancer Res. 2017;77:6524-6537.
     PubMed     Abstract available
     
     
     November 2017
104. MARTIN-MARTIN N, Zabala-Letona A, Fernandez-Ruiz S, Arreal L, et al
     PPARdelta elicits ligand-independent repression of Trefoil Factor Family to limit prostate cancer growth.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0908.
     PubMed     Abstract available
     
     
     
105. EMERSON MA, Banegas MP, Chawla N, Achacoso N, et al
     Disparities in Prostate, Lung, Breast, and Colorectal Cancer Survival and Comorbidity Status among Urban American Indians and Alaskan Natives.
     Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0429.
     PubMed     Abstract available
     
     
     
106. ALEXANDER J, Kendall J, McIndoo J, Rodgers L, et al
     Utility of single cell genomics in diagnostic evaluation of prostate cancer.
     Cancer Res. 2017 Nov 27. pii: 0008-5472.CAN-17-1138.
     PubMed     Abstract available
     
     
     
107. MURPHY SJ, Kosari F, Karnes RJ, Nasir A, et al
     Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer.
     Cancer Res. 2017;77:6157-6167.
     PubMed     Abstract available
     
     
     October 2017
108. KIM S, Alsaidan OA, Goodwin O, Li Q, et al
     Blocking myristoylation of Src inhibits its kinase activity and suppresses prostate cancer progression.
     Cancer Res. 2017 Oct 16. pii: canres.0981.2017.
     PubMed     Abstract available
     
     
     
109. PONNUSAMY S, Coss CC, Thiyagarajan T, Watts K, et al
     Novel selective agents for the degradation of androgen receptor variants to treat castration-resistant prostate cancer.
     Cancer Res. 2017 Oct 4. pii: canres.0976.2017.
     PubMed     Abstract available
     
     
     
110. DAMASCHKE NA, Yang B, Bhusari S, Avilla M, et al
     Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth.
     Cancer Res. 2017;77:5236-5247.
     PubMed     Abstract available
     
     
     September 2017
111. SAN MARTIN R, Pathak R, Jain A, Jung SY, et al
     Tenascin-C and integrin alpha9 mediate interactions of prostate cancer with the bone microenvironment.
     Cancer Res. 2017 Sep 15. pii: canres.0064.2017.
     PubMed     Abstract available
     
     
     
112. LIANG Y, Ahmed M, Guo H, Soares F, et al
     LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.
     Cancer Res. 2017 Sep 15. pii: canres.0496.2017.
     PubMed     Abstract available
     
     
     August 2017
113. WANG L, Song G, Zhang X, Feng T, et al
     PADI2-mediated citrullination promotes prostate cancer progression.
     Cancer Res. 2017 Aug 17. pii: canres.0150.2017.
     PubMed     Abstract available
     
     
     
114. JIN L, Garcia J, Chan E, de la Cruz C, et al
     Therapeutic targeting of the CBP/p300 bromodomain blocks the growth of castration-resistant prostate cancer.
     Cancer Res. 2017 Aug 17. pii: canres.0314.2017.
     PubMed     Abstract available
     
     
     
115. SCHER HI, Graf RP, Schreiber N, McLaughlin B, et al
     Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.
     Cancer Res. 2017 Aug 17. pii: canres.1353.2017.
     PubMed     Abstract available
     
     
     
116. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
     Targeting a single alternative polyadenylation site coordinately blocks expression of androgen receptor mRNA splice variants in prostate cancer.
     Cancer Res. 2017 Aug 15. pii: canres.0320.2017.
     PubMed     Abstract available
     
     
     
117. VAN ETTEN JL, Nyquist M, Li Y, Yang R, et al
     Targeting a Single Alternative Polyadenylation Site Coordinately Blocks Expression of Androgen Receptor mRNA Splice Variants in Prostate Cancer.
     Cancer Res. 2017 Aug 15. doi: 10.1158/0008-5472.CAN-17-0320.
     PubMed     Abstract available
     
     
     
118. BAINOR AJ, Deng FM, Wang Y, Lee P, et al
     Chromatin-associated protein SIN3B prevents prostate cancer progression by inducing senescence.
     Cancer Res. 2017 Aug 14. pii: canres.3410.2016.
     PubMed     Abstract available
     
     
     July 2017
119. YIN Y, Li R, Xu K, Ding S, et al
     Androgen receptor variants mediate DNA repair after prostate cancer irradiation.
     Cancer Res. 2017 Jul 28. pii: canres.0164.2017.
     PubMed     Abstract available
     
     
     
120. 
     Correction: MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer.
     Cancer Res. 2017;77:3961.
     PubMed    
     
     
     
121. SAHA A, Ahn S, Blando J, Su F, et al
     Proinflammatory CXCL12-CXCR4/CXCR7 signaling axis drives Myc-induced prostate cancer in obese mice.
     Cancer Res. 2017 Jul 7. pii: canres.0284.2017.
     PubMed     Abstract available
     
     
     June 2017
122. LOVERIDGE CJ, Mui EJ, Patel R, Tan EH, et al
     Increased T-cell Infiltration Elicited by Erk5 Deletion in a Pten-Deficient Mouse Model of Prostate Carcinogenesis.
     Cancer Res. 2017;77:3158-3168.
     PubMed     Abstract available
     
     
     
123. WANG Y, Wang J, Zhang L, Karatas OF, et al
     RGS12 is a novel tumor suppressor gene in African American prostate cancer that represses AKT and MNX1 expression.
     Cancer Res. 2017 Jun 13. pii: canres.0669.2017.
     PubMed     Abstract available
     
     
     May 2017
124. 
     Correction: Metastatic Progression of Prostate Cancer Is Mediated by Autonomous Binding of Galectin-4-O-Glycan to Cancer Cells.
     Cancer Res. 2017;77:2772.
     PubMed    
     
     
     
125. MALEK R, Gajula RP, Williams RD, Nghiem B, et al
     TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis.
     Cancer Res. 2017 May 8. pii: canres.2797.2016.
     PubMed     Abstract available
     
     
     
126. PALTOGLOU S, Das R, Townley SL, Hickey T, et al
     Novel androgen receptor co-regulator GRHL2 exerts both oncogenic and anti-metastatic functions in prostate cancer.
     Cancer Res. 2017 May 4. pii: canres.1616.2016.
     PubMed     Abstract available
     
     
     
127. IBRAHIM-HASHIM A, Robertson-Tessi M, Enriquez-Navas PM, Damaghi M, et al
     Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution.
     Cancer Res. 2017;77:2242-2254.
     PubMed     Abstract available
     
     
     April 2017
128. KOLONIN MG, Sergeeva A, Staquicini DI, Smith TL, et al
     Interaction between tumor cell surface receptor RAGE and proteinase 3 mediates prostate cancer metastasis to bone.
     Cancer Res. 2017 Apr 20. pii: canres.0708.2016.
     PubMed     Abstract available
     
     
     
129. WEN D, Peng Y, Lin F, Singh RK, et al
     Micellar delivery of miR-34a modulator rubone and paclitaxel in resistant prostate cancer.
     Cancer Res. 2017 Apr 20. pii: canres.2355.2016.
     PubMed     Abstract available
     
     
     
130. CHEN HY, Larson PEZ, Bok RA, von Morze C, et al
     Assessing Prostate Cancer Aggressiveness with Hyperpolarized Dual-Agent 3D Dynamic Imaging of Metabolism and Perfusion.
     Cancer Res. 2017 Apr 20. pii: canres.2083.2016.
     PubMed     Abstract available
     
     
     March 2017
131. KURMIS AA, Yang F, Welch TR, Nickols NG, et al
     A pyrrole-imidazole polyamide is active against enzalutamide-resistant prostate cancer.
     Cancer Res. 2017 Mar 30. pii: canres.2503.2016.
     PubMed     Abstract available
     
     
     
132. WEI X, Xu Y, Xu FF, Chaiswing L, et al
     RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells.
     Cancer Res. 2017;77:1345-1356.
     PubMed     Abstract available
     
     
     
133. OH DY, Cham J, Zhang L, Fong G, et al
     Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
     Cancer Res. 2017;77:1322-1330.
     PubMed     Abstract available
     
     
     February 2017
134. MANZO T, Sturmheit T, Basso V, Petrozziello E, et al
     T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFalpha Expression and Empower Adoptive Cell Therapy for Solid Tumors.
     Cancer Res. 2017;77:658-671.
     PubMed     Abstract available
     
     
     January 2017
135. BERNICHTEIN S, Pigat N, Barry Delongchamps N, Boutillon F, et al
     Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation.
     Cancer Res. 2017;77:355-365.
     PubMed     Abstract available
     
     
     April 2016
136. LINDQUIST KJ, Paris PL, Hoffmann TJ, Cardin NJ, et al
     Mutational Landscape of Aggressive Prostate Tumors in African American Men.
     Cancer Res. 2016;76:1860-8.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: